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Introduction
Exome Sequencing (ES) is the current standard of care diagnostic tool for identifying a molecular cause(s) in individuals with suspected Mendelian disorders 1 . Identifying single nucleotide variants (SNVs) and small insertion/deletions (indels) from next-generation sequencing (NGS) data have been well studied and characterized 2, 3 . Success has been elusive to date to detect copy-number variants (CNVs) from NGS data with the same confidence as the SNVs/indels. Chromosomal microarrays (CMA) arrays are still the preferred methodology for detecting genome-wide CNVs 4 . CNV detection using ES is not currently a routine clinical test, likely due to the overwhelming inconsistencies among different methods [5] [6] [7] and the lack of a high-quality reference for CNVs from ES data. Most of the algorithms for CNV detection from ES data use the depth of coverage of exome targets under the assumption that the read depth is linearly correlated with the underlying true copy number at any given locus. However, the readdepth in ES is known to be extremely variable and influenced by several factors such as sample batching, GC-content, PCR duplication bias, targeted depth, sequencing efficiency and mappability 8, 9 . These factors make it difficult to differentiate between technical artifacts and the real signal for a true copy-number change. Also, detecting CNVs in polymorphic regions of the genome is challenging as the methods for ES-based CNV are estimating copy-number relative to the average copy-number of the control samples.
While the sensitivity of several software tools for ES-based CNV has been published, reports of false-discovery rate and the reproducibility 7, 10 are limited. Quality and performance standards for a clinical pipeline is set at the highest level possible as it has direct implications on patients' health and disease management. In spite of the availability of several computational tools to detect CNVs from ES [11] [12] [13] [14] , clinical labs have been slow to adopt the incorporation of CNV detection in their ES. However, some of the recent reports support the argument for copynumber detection from ES in a clinical setting [15] [16] [17] .
In this work, we used a cohort of samples with clinical CMA and ES data to create a dataset of high-quality true-positive CNVs from CMA and comprehensively characterize the CNVs identified from ES data, as described in Table 1 . We addressed some of the rarely discussed issues such as false-discovery rate, false-negatives, and reproducibility. In addition, we propose a modified analysis workflow to reduce false-positives. Finally, we show that ES data can be used reliably for detecting clinically-relevant CNVs with high sensitivity in a reproducible manner for use in a clinical diagnostic setting.
Materials and Methods

Cohort
A cohort of 395 individuals who were referred to the Genomic Diagnostic Laboratory (GDL) at the Children's Hospital of Philadelphia (CHOP), Philadelphia PA for genetic testing and had both clinical CMA and ES data was collected for this study. We used a larger cohort including an additional 1,585 individuals with both affected individuals referred for genetic testing and their relatives as controls for read-depth normalization and targeted STRC testing (n=1,972). All of the ES data were produced using the Agilent SureSelect V5 plus target capture kit (Agilent Technologies, Santa Clara, CA) and the aligned BAM files were produced using the workflow described elsewhere 18 . All of the ES data were generated at the same sequencing center in 112 different batches over 2 years. These samples were analyzed as part of a process improvement program within the GDL at CHOP.
CNV from Exome sequencing (ES)
We used a custom CNV detection pipeline and analysis workflow using the R package ExomeDepth 19 with default parameters and exon definitions provided along with the package.
ExomeDepth creates a custom reference sample set by choosing the most correlated samples from a larger cohort of controls and identifies CNVs based on relative read-depth of the test sample compared against this custom reference. Further details of this method is described elsewhere 19 . Mean number of CNVs per sample identified in the entire cohort were calculated.
On average each sample had 164 CNVs with the default pipeline and the standard deviation was 27. Samples with number of CNVs identified greater than two standard deviations from the mean were excluded as outliers. There were 8 such outlier samples that were excluded and the final sample size was 387 (207 males and 187 females). Summary statistics of the CNVs identified from the ES are provided in the Table 2 All coordinates are in GRCh37.
CNVs from SNP arrays
SNP array data were generated using three different platforms, Illumina CytoSNP 850k chip v1.0 (n=142) and v1.1 (n=165), Illumina Omni1 Quad (n=28) and Illumina Quad610 (n=52). Poorly performing probes and probes within highly polymorphic CNV regions (>10% internal cohort) were removed prior to CNV calling. CNVs from SNP arrays were called using CNV-workshop 20 or PennCNV 21 . CNVs involving fewer than 10 probes were excluded, as the rate of false positives increases with fewer number of probes 22 . We excluded any CNVs called in the chromosome Y due to lack of coverage on both the array and exome capture. CNVs identified from the Quad610 arrays were in hg18 genome build and the liftOver 23 tool from UCSC was used to convert the genomic coordinates to GRCh37. CNVs that were split in the genome build were excluded prior to any analysis.
Defining gold standard high-quality true-positive CNVs from clinical SNP arrays
We considered several factors while defining the gold standard baseline true positive dataset for CNVs from CMA, as it dictates the resulting sensitivity of the ES. In order to perform a reasonable comparison between these platforms, we first limited the CNVs from arrays to have at least one coding exon and at least one bait in the ES design, and overlap at least 10 SNP probes in order to minimize the number of false positive and false negatives from the CMA data set. In cases where we detected a CNV in the array but not in the ES, we manually reviewed the raw data from CMA to determine if the call was a false negative in the ES or a false positive in the CMA. This process was mainly performed to refine the baseline true positive calls as even the list of CNVs overlapping at least 10 probes is likely to have its own false positive and false negative rates. Failing to remove the putative false positives from the CMA will deflate the actual sensitivity of the ES.
In our validation cohort with the SNP array data, there were a total of 9,033 CNVs prior to exclusion. Applying the exclusion criteria resulted in 634 CNVs (589 in the autosomes and 45 in the chromosome X). These 634 CNVs formed our initial true positive dataset for comparison against the CNV calls from ES data. Fifty-five of these CNVs were not detected in the ES data. These discrepant calls were manually reviewed, and 41 were confirmed to be true positives in the array, seven were false positives in the array, and seven were ambiguous. The fourteen CNVs that were either not present or ambiguous in the CMA were excluded and the revised baseline true positive dataset contained 620 CNVs (576 autosomal and 44 chromosome X variants). Details of this filtering cascade are provided in Table 2 . The final list of all the true positive CNVs is provided in Supp. Table 1 .
Estimating false discovery rate of CNV from ES
To estimate the false discovery rate of the ExomeDepth pipeline, we reviewed CNVs 
Modifying the existing workflow
We used the 35-mer mappability score 25 from the UCSC genome browser (link) and excluded any exon with a mean mappability score less than 0.75 prior to variant calling. We excluded 8,527 out of the total 190,340 unique exons we used in the initial experiment prior to calling the CNVs. We applied the modified regions of interest to both the 387 samples, plus a larger cohort of 1,585 samples to assess the effect of this filter on the clinically-relevant gene STRC, which is known to have a pseudogene with 99.6% sequence identity.
Reproducibility of the ExomeDepth pipeline
To test the effect of the control cohort on reproducibility, we ran 1,000 iterations of our pipeline for each of the 387 samples, along with a subset of 200 controls randomly chosen from a larger control cohort of 1,585 samples. We kept track of 1) the number of reference samples selected, 2) batch from which the control sample was sequenced, 3) correlation of the coverage between the test and the reference samples, and 4) the CNV calls produced. We also specifically looked at 59 clinically reported variants in 53 individuals for their reproducibility over the 1,000
iterations.
Validation of CNVs using Droplet-Digital PCR (ddPCR)
All diagnostic CNVs and a subset of STRC CNVs were chosen for confirmation using PCR across the breakpoints, droplet digital PCR (ddPCR), or long-range PCR, using standard protocols used in the clinical laboratory 26 .
Results
Using a cohort of 387 samples, we validated an exome-based CNV detection pipeline using the R package ExomeDepth 19 for use in a clinical setting, by comparing the results against data from a high-quality set of true positive CNVs from CMA. We chose ExomeDepth after a pilot study comparing other software such as XHMM 11 , CoNIFER 12 , and CODEX
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ExomeDepth was the most sensitive of the algorithms tested and the union of results from all three were no better than ExomeDepth alone (data not shown). We estimated the true positive and false discovery rates and implemented a modified bioinformatics pipeline to reduce the total number of CNVs identified and the number of false positives. Finally, we estimated the reproducibility of 59 clinically reported CNVs in 53 patients by running 1,000 experiments per sample along with randomly chosen subsets of controls from a larger cohort.
True positive rate
Overall, the default ES pipeline had a 94% true positive rate for both deletions (219/234) and duplications (360/ 386). In the exomes, 96% percent of the true positives were identified as single contiguous CNVs and the rest as two CNV calls. The ES pipeline identified all homozygous deletions (n=14), hemizygous deletions (n=2) and triplications (n= 5). Sensitivity for the autosomes was 94% (539/576) compared to the chromosome X at 91% (40/44).
Clinically reported variants were detected 100% of the time (58/58). Summary of sensitivity rates for various CNV classes are provided in the Table 4 .
There were 41 CNVs that were found in CMA and were not identified by our exome Details of the CNVs missed by the exome pipeline are provided in the Supp. Table 2 .
False discovery rate
In order to determine the false discovery rate from ES, we analyzed CNVs identified by the ES pipeline that were not a part of the CMA true positive set, and overlap with at least 10 probes on the array. Of the 122 CNVs reviewed, 22 (18%) were determined to be real in the CMA and one was determined to be real but with an opposite copy-number state in a polymorphic region, likely due difference in the average copy-number state in the controls.
Ninety-nine (82%) of the CNVs were deemed to be false-positives in the ES data. Details of the CNVs identified from the exomes and not by the CMA are provided in the Supp. Table 3 .
Modified ES workflow
Manual review of the false-positive CNV calls from ES data suggested that a large number of those calls were identified in regions with high homology elsewhere in the genome or regions with low sequence complexity. To mitigate this effect, we used a mappability filter to exclude exons that have difficulty in mapping short-read NGS data 27 With the modified workflow, we identified a total of 76 STRC CNVs (29 deletions and 47 duplications) in 76 individuals (4% of the samples). Of these, we performed confirmatory testing on 6 duplications and 24 deletions using ddPCR, 2 single-exon deletions by long range PCR, and 3 multi-exon deletions by CMA. We were able to confirm all multi-exonic deletions and duplications, and the single-exon deletions were found to be associated with gene conversion events involving exon 26 and exon 24. Details of the validation data are provided in the Supp. Table 4 .
Reproducibility
Previous reports suggest that, among other factors, the choice of the control cohort affects the CNVs identified from ES data. To understand the effect of the choice of the control cohort, we estimated reproducibility of our pipeline by running 1,000 iterations for every sample with 200 random controls and counted the number of times the clinically reported CNVs were called.
Over these 387,000 experiments, the average number of calls per sample across iterations was 60
for the autosomes (median = 50) and 2 for the X chromosome (median = 1.4). The number of batches from which these reference samples came ranged from 3 to 14 (mean = 9). There was a total of 3,204 CNVs in the cohort that were identified in all 1,000 iterations, with a mean of 8
CNVs per individual. Of these CNVs which met criteria to be called by the array (n=221), 179
were also identified by the CMA (81%). To resolve the discrepant calls (n=42), we manually reviewed a subset of CNVS (n=14) and confirmed that 12 out of the 14 were actually false negatives in the CMA. Of all the CNVs we were able to confirm with array data, 190 out of 192
CNVs were real and reproducible. As for the clinically-reported variants, all 59 were identified in all 1,000 experiments for those samples.
New diagnoses
In the process of the validation, several previously unrecognized clinically significant CNVs were discovered. All of the probands included in the cohort (n = 351) were referred to exome sequencing after a negative or inconclusive SNP array. We made a total of 5 new molecular diagnoses in 5 individuals who had negative or inconclusive results with the SNV/indel only pipeline or previously not identified in the SNP array (overlapping fewer than 10 probes in the SNP array) or not being in a known disease-causing gene at the time of reporting.
Where possible, we were able to determine the exact breakpoints for three deletions from the chimeric reads in the exome data and validated these using Sanger sequencing across the breakpoints. The details of the new diagnoses are provided in the Table 5 . These pathogenic
CNVs included 1 to 9 exons, in both autosomal dominant and recessive disease associated genes.
Discussion
Detecting CNVs from ES data is perceived as challenging for clinical use as many previously published reports suggested high false positive rates and low sensitivity. In this work, we used a cohort of 387 individuals to systematically and comprehensively benchmark the ability to detect
CNVs from exome sequencing data using the ExomeDepth pipeline. Prior benchmarking efforts have attempted to use data from multiple orthogonal platforms and algorithms for estimating sensitivity and specificity from ES data 7, 27, 28 . Performance metrics such as sensitivity and falsediscovery rate rely solely on the baseline true positive set. Factors influencing such comparisons should be considered carefully before defining the true positive set as the resulting performance metrics may be misleading. Our diagnostic lab uses a 10-probe threshold for CMA data as CNVs overlapping fewer probes are known to have a higher rate of false positives 22 . ES has poor sequencing efficiency in GC-rich regions, in segmental duplicated regions, and in regions with low sequence complexity 8, 9 . Also, the sequencing is based on a target design which may or may not include regions of the genome that is captured by an alternative technology. Taking the inherent limitations of both the ES and CMA technology into account allowed for the maximization of the clinical utility of the ES data. Several algorithms exist for detecting CNVs from ES and there is a trade-off between the true positive rate (detecting the true CNVs) and false discovery rate (detecting false positives). For use in a clinical setting, one requires the highest sensitivity and lowest false discovery rate possible for a given platform.
We defined a high-quality baseline true positive set for CNVs using data from CMA and found that ES is 93% sensitive for both deletions and duplications using the default settings of the ExomeDepth pipeline. The analysis of CNVs missed by ES (false negatives) revealed that 80% of them were in highly polymorphic or segmental duplicated regions and 31% of them involved first or last exons. First exons are known to be GC rich and GC-content greatly influences the depth of coverage 11 . However, there is no prior evidence associating last coding exons with non-uniform depth of coverage during exome sequencing. Analysis of false positives showed a similar trend with 89% located in overlapping regions that are polymorphic in the general population, of low sequence complexity, or of segmental duplications. The ExomeDepth pipeline coupled with a mappability threshold for including exons before calling the CNVs reduced the number of calls to one third which reduced the burden of downstream analysis and validation. In addition, we were able to detect CNVs in the clinically-relevant and difficult regions, such as STRC, with high specificity.
Using this pipeline, we were able to make new diagnoses in five individuals who had previous negative CMA tests, demonstrating the utility of this assay for small (1 exon to multiexon CNVs), intragenic CNVs below the clinical reporting threshold for CMA. The results from the ExomeDepth pipeline were 100% reproducible for clinically reported variants with control datasets generated from over 112 batches over a period of 2 years, even though sample batching is known to be strongly correlated with the variability in the depth of coverage observed in ES data 11 .
Despite our positive results, some challenges still exist. For example, it is challenging to determine the exact copy-number state in the highly variable regions of the genome and these regions pose a challenge irrespective of the technology used. A large number of true positives and larger cohorts with homogeneous samples may be required to optimize CNV calling in such polymorphic regions. Detecting CNVs in genes with near identical homologs elsewhere in the genome is an intractable problem when using short-read sequencing data. These regions often result in both false positive and false negative CNV calls. Using an exon-level mean mappability score threshold helps in reducing the false positives but it also excludes some clinically relevant genes completely (eg. SMN1 and SMN2). On the other hand, this mappability filter still allows the inclusion of exons with partial regions of poor mappability, resulting in numerous false positives. The 100% validation rate we observed for the STRC gene deletions and duplications after using the mappability-based filter is encouraging and further work is warranted to understand the effect on similar regions elsewhere in the genome. In spite of being able to detect the clinically reported CNVs 100% of the time in our reproducibility experiments, we found that the choice of controls and the batch in which the controls were sequenced had an effect on the total number of CNVs identified. Only a small subset of variants per sample were identified across all 1,000 iterations and manual verification of these CNVs suggest that they have a higher likelihood of being real. While the number of times a variant is reproduced with different control cohorts may indicate the robustness of the call, it is also likely that technical artifacts are also reproducible. It is important to note that all of our controls are generated in the same sequencing facility with the same protocol. Using data produced from different sequencing protocols, target captures, and sequencing centers could affect the reproducibility and produce erroneous results.
Further experimentation is warranted to utilize this information along with other quality metrics for better ranking of likely true positive variants. Validation of clinically-relevant CNVs using an orthogonal method is important before reporting to the patients as ES-based CNV detection is still relative to the control cohort used. However, maintaining good practices in creating a control cohort, a validation pipeline with a variety of known variants types and size, and stringent quality control before clinical correlation will reduce the burden of validations using orthogonal methods.
In summary, our work demonstrates the ability to detect CNVs from ES data in a reliable and reproducible manner in a clinical setting. Integrating CNVs in a clinical workflow may help in finding molecular diagnoses for unresolved patients with one pathogenic variant (SNV/indel) in an autosomal recessive disease gene, and increase the overall diagnostic rate. We expect targeted NGS to be used in diagnostics for a considerable amount of time given the lower cost, focused approach and reduced burden on downstream analysis compared to genome sequencing.
Thus, it is important to continue to invest in resources and refine the existing tools for making ES a better diagnostic test overall. Step 1 Defining the initial gold standard
Filter for CNVs that overlap at least 10 probes in the array and one bait in the exome design
Step 2 Estimate the initial sensitivity
Estimate initial sensitivity by comparing CNV from ES and CMA and review false-negatives in the exome
Step 3
Refine the goldstandard CNVs and sensitivity
Remove false-positives in the CMA data and recalculate sensitivity
Step 4 Estimate the false discovery rate
Manually verify CNVs called by exome that overlap at least 10 probes and not identified by the array
Step 5 Analyze the false positives
Analyze false-positives to identify factors that influence CNV calling from ES data
Step 6 Modify the workflow Use mappability filter to exclude regions of high homology and reduce false-positives
Step 7 Estimate the reproducibility
Estimate reproducibility of ES-based CNV workflow by performing tens of thousands of experiments with randomized control cohorts Table 5 . New diagnoses made by the ES pipeline that were previously not reported.
